Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Consequently, research teams can develop repeatable procedures that support scientific consistency, organized documentation, and dependable analytical practices
In addition, the pathways Lipid and atherosclerosis and Fluid shear stress and atherosclerosis may be involved in lipid metabolic disease
We have shown that self-report data is a complementary instrument for collecting data regarding treatment response that is qualitatively consistent with medical records, while also enabling collection of information regarding side effects that may not be readily available in EHRs
Medications offered through Peak Wellness Peak Wellness keeps their medication menu intentionally narrow
10.1016/j.jtos.2020.02.009 194 WykrotaA
